Prestige Consumer Healthcare Inc. $PBH Shares Sold by Great Lakes Advisors LLC

Key Points

• Great Lakes Advisors LLC reduced its stake in Prestige Consumer Healthcare Inc. by 9.1% during the first quarter, resulting in ownership of approximately 126,502 shares worth about $10,875,000.
• Prestige Consumer Healthcare reported a net margin of 19.02% and earnings of $0.95 per share, which fell short of analysts' expectations of $1.01.
• Analyst ratings on Prestige Consumer Healthcare are mixed, with a consensus rating of "Hold" and a target price of $93.33, reflecting caution in the stock's outlook.

Great Lakes Advisors LLC lessened its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 9.1% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 126,502 shares of the company's stock after selling 12,614 shares during the quarter. Great Lakes Advisors LLC owned 0.26% of Prestige Consumer Healthcare worth $10,875,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kayne Anderson Rudnick Investment Management LLC acquired a new position in Prestige Consumer Healthcare during the 4th quarter worth approximately $84,932,000. Invesco Ltd. lifted its position in Prestige Consumer Healthcare by 24.7% during the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock worth $113,635,000 after acquiring an additional 261,537 shares in the last quarter. GAMMA Investing LLC lifted its position in Prestige Consumer Healthcare by 11,580.3% during the 1st quarter. GAMMA Investing LLC now owns 161,538 shares of the company's stock worth $13,887,000 after acquiring an additional 160,155 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock worth $46,997,000 after acquiring an additional 120,965 shares in the last quarter. Finally, Neumeier Poma Investment Counsel LLC acquired a new position in Prestige Consumer Healthcare during the 1st quarter worth approximately $8,713,000. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH traded down $1.71 during trading on Friday, reaching $63.31. The stock had a trading volume of 560,980 shares, compared to its average volume of 569,221. Prestige Consumer Healthcare Inc. has a one year low of $62.95 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The stock has a market cap of $3.12 billion, a PE ratio of 14.86, a P/E/G ratio of 2.06 and a beta of 0.46. The firm's 50 day moving average price is $70.53 and its two-hundred day moving average price is $79.23.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm had revenue of $249.53 million during the quarter, compared to the consensus estimate of $260.71 million. During the same quarter last year, the firm posted $0.90 earnings per share. Prestige Consumer Healthcare's revenue was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Zacks Research lowered Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th. Canaccord Genuity Group reduced their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Prestige Consumer Healthcare currently has an average rating of "Hold" and a consensus price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.